^
7d
Non-secreting IL12 expressing oncolytic adenovirus Ad-TD-nsIL12 in recurrent high-grade glioma: a phase I trial. (PubMed, Nat Commun)
Complete response (according to Response Assessment in Neuro-Oncology Criteria) in one patient, a partial response in one patient and post-treatment infiltrations of CD4+ and CD8 + T cells into the tumour were documented during this trial. In conclusion, Ad-TD-nsIL12 has demonstrated safety and preliminary efficacy in patients with recurrent high-grade glioma.
P1 data • Journal • Oncolytic virus
|
CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
22d
Pembrolizumab with Intratumoral Injection of Clostridium Novyi-NT (clinicaltrials.gov)
P1, N=18, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Oct 2024 --> Oct 2026 | Trial primary completion date: Oct 2024 --> Oct 2026
Trial completion date • Trial primary completion date • Combination therapy
|
PD-L1 (Programmed death ligand 1)
|
Keytruda (pembrolizumab) • Clostridium novyi-NT
25d
NeoLIPA: Neoadjuvant LTX-315 in Combination with Pembrolizumab in Resectable Stage III/IV Melanoma (clinicaltrials.gov)
P2, N=27, Recruiting, Oslo University Hospital | Not yet recruiting --> Recruiting
Enrollment open
|
Keytruda (pembrolizumab) • Oncopore (ruxotemitide)
1m
MP-11: Moderated Oral ePoster Session: Kidney and Ureteral Cancer - Clinical (SIU 2024)
MP-10.01 Diffusion-Weighted Magnetic Resonance Imaging for Assessment of Tumor Response in Muscle-Invasive Bladder Cancer Patients Undergoing Neoadjuvant Chemotherapy: A Prospective StudyAbbas Basiri, Iran, Islamic Rep. MP-10.02 Divergent Experiences of Bladder Cancer Patients: A Focus on Advanced and Metastatic Disease StagesAlex Filicevas, Belgium MP-10.03 Evolution of a Rapid, Simple Urine Test for Detecting Volatile Organic Compound (VOC) in Urine by a High Performance Portable Device (NABIL) for Detection of Urinary Bladder CarcinomaSaurav Karmakar, India MP-10.04 Intraoperative ICG Fluorescence as a Method of Prevention of Postoperative Strictures of Uretero-Ileoanastomoses During Robot-Assisted Radical CystectomyValentin Pavlov, Russian Federation MP-10.05 Intravesical Gemcitabine and Docetaxel in Patients with High Risk NMIBC: Our ExperienceDeepak Krishnappa, India MP-10.06 On Block Robot-Assisted Radical Cystectomy: New Method for Bladder CancerValentin Pavlov, Russian Federation MP-10.07 Oncological Outcomes with the 80mg Dose of the Moscow Strain of Intravesical BCG for Non-Muscle Invasive Bladder Cancer: Implications for Global ShortageAmandeep Arora, India MP-10.08 Outcome of Robot-Assisted Radical Cystectomy with Intracorporeal Creation of Heterotopic NeocystisValentin Pavlov, Russian Federation MP-10.09 Proposed Novel Surveillance Schedule Using Cx Monitor for Patients on Annual Bladder Cancer SurveillanceArjun Guduguntla, Australia MP-10.10 Quality of Primary TURBTs for Non-Muscle Invasive Bladder Cancer PatientsSaurabh Verma, United Kingdom MP-10.11 TAR-200 in Patients with Bacillus Calmette-Guérin-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer: Results from the SunRISe-1 StudyAndrea Necchi, United States MP-10.12 Timeline Analysis of Muscle Invasive Bladder Cancer PatientsSaurabh Verma, United Kingdom MP-10.13 Transurethral Resection of Bladder Tumour (TURBT) Operative Notes: How to Improve Their QualitySaurabh Verma, United Kingdom MP-10.14 Trial in Progress: PIVOT-006- A Phase 3, Randomized Study of Adjuvant Intravesical Cretostimogene Grenadenorepvec versus Surveillance for the Treatment of Intermediate-Risk Non-Muscle Invasive Bladder Cancer Following Transurethral Resection of Bladder TumorRobert Svatek, United States MP-10.15 URO17® Urine Test For Bladder Cancer - Meta AnalysisNikhil Vasdev, United Kingdom MP-10.16 Usefulness of UF-5000 Automatic Screening System in Urothelial Carcinoma DiagnosisTadahiko Kikugawa, Japan MP-10.17 Validation of Novel ddPCR Bladder Cancer DNA Mutation Panels in Liquid BiopsiesAntara Karmakar, Australia
Clinical
|
URO17™
|
docetaxel • GemRIS (gemcitabine-releasing intravesical system) • cretostimogene grenadenorepvec (CG0070)
1m
New P2 trial • Combination therapy
|
Keytruda (pembrolizumab) • Oncopore (ruxotemitide)
1m
VP-315-201: Open-Label Proof of Concept Study of VP-315 in Basal Cell Carcinoma (clinicaltrials.gov)
P2, N=92, Completed, Verrica Pharmaceuticals Inc. | Recruiting --> Completed
Trial completion
|
Oncopore (ruxotemitide)
1m
Cancer cell-selective induction of mitochondrial stress and immunogenic cell death by PT-112 in human prostate cell lines. (PubMed, J Transl Med)
Our data provide additional insight into mitochondrial stress and ICD in response to PT-112. PT-112 anticancer immunogenicity could have clinical applications and is currently under investigation in a Phase 2 mCRPC study.
Preclinical • Journal
|
CASP3 (Caspase 3)
|
imifoplatin (PT-112)
2ms
VIRAGE: Study of Nab-Paclitaxel and Gemcitabine and Plus/minus VCN-01 in Patients with Metastatic Pancreatic Cancer (clinicaltrials.gov)
P2, N=96, Active, not recruiting, Theriva Biologics SL | Recruiting --> Active, not recruiting
Enrollment closed • Metastases
|
gemcitabine • albumin-bound paclitaxel • VCN-01
2ms
Enrollment open
|
cretostimogene grenadenorepvec (CG0070)
2ms
MC1372: Vaccine Therapy in Treating Patients with Malignant Peripheral Nerve Sheath Tumor That is Recurrent or Cannot Be Removed by Surgery (clinicaltrials.gov)
P1, N=9, Completed, Mayo Clinic | Recruiting --> Completed | N=30 --> 9 | Trial completion date: Sep 2024 --> Apr 2024 | Trial primary completion date: Sep 2024 --> Apr 2024
Trial completion • Enrollment change • Trial completion date • Trial primary completion date • Surgery
|
MV-NIS
2ms
MANHATTAN: A Study of MFA-370 in Patients with Metastatic Urothelial Cancer (clinicaltrials.gov)
P1/2, N=0, Withdrawn, Ectin Research AB | N=50 --> 0 | Trial completion date: Dec 2024 --> Dec 2025 | Not yet recruiting --> Withdrawn | Trial primary completion date: Dec 2024 --> Dec 2025
Enrollment change • Trial completion date • Trial withdrawal • Trial primary completion date • Metastases
2ms
Keynote 935: Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin (clinicaltrials.gov)
P2, N=35, Completed, CG Oncology, Inc. | Active, not recruiting --> Completed | Trial completion date: Jun 2023 --> May 2024
Trial completion • Trial completion date • Combination therapy
|
Keytruda (pembrolizumab) • cretostimogene grenadenorepvec (CG0070)
2ms
A Study to Find a Suitable Dose of BI 1821736 and Test Whether it Helps People With Advanced Cancer (clinicaltrials.gov)
P1, N=27, Suspended, Boehringer Ingelheim | Trial completion date: Nov 2025 --> Jan 2027 | Recruiting --> Suspended | Trial primary completion date: Nov 2024 --> Jan 2026
Trial completion date • Trial suspension • Trial primary completion date • Metastases
|
BI 1821736
2ms
Y-box binding protein 1/cyclin A1 axis specifically promotes cell cycle progression at G2/M phase in ovarian cancer. (PubMed, Sci Rep)
YBX1 mRNA levels were significantly correlated with cyclin A1 mRNA levels in patients with high-grade serous carcinoma. Augmented YBX1 expression plays a key role in tumor growth promotion in ovarian cancer in its close association with cyclin A1.
Journal
|
YBX1 (Y-Box Binding Protein 1) • CCNA1 (Cyclin A1)
2ms
New trial • Combination therapy • Real-world evidence • Real-world • Metastases
|
Opdivo (nivolumab) • vusolimogene oderparepvec (RP1)
3ms
Calcium ion delivery by microbubble-assisted sonoporation stimulates cell death in human gastrointestinal cancer cells. (PubMed, Biomed Pharmacother)
These promising results encourage future research to optimize sonoporation parameters for clinical use, investigate synergistic effects with existing treatments, and assess long-term safety and efficacy in vivo. Our study highlights CaSP's clinical potential for improved safety and efficacy in cancer therapy, offering significant implications for the pharmaceutical and biomedical fields.
Journal
|
TP53 (Tumor protein P53)
3ms
RTB: Evaluate Safety and the Oncolitic Adenovirus VCN-01 Activity in Patients With Refractory Retinoblastoma (clinicaltrials.gov)
P=N/A, N=13, Completed, Fundació Sant Joan de Déu | Active, not recruiting --> Completed
Trial completion • Oncolytic virus
|
RB1 (RB Transcriptional Corepressor 1)
|
VCN-01
3ms
New P2 trial
|
cretostimogene grenadenorepvec (CG0070)
3ms
New P1 trial • Oncolytic virus
3ms
Enrollment open • Oncolytic virus
|
Avastin (bevacizumab) • cisplatin • carboplatin • albumin-bound paclitaxel • KM1
4ms
Enrollment open • Combination therapy • Metastases
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • temozolomide • albumin-bound paclitaxel • Opdualag (nivolumab/relatlimab-rmbw) • relatlimab (BMS-986016) • vusolimogene oderparepvec (RP1)
4ms
AM003-FIH-001: Study of AM003 in Patients With Locally Advanced and Metastatic Solid Tumors (clinicaltrials.gov)
P1, N=12, Active, not recruiting, Aummune Ltd. | Recruiting --> Active, not recruiting | Trial completion date: Jun 2024 --> Jan 2025
Enrollment closed • Trial completion date • Metastases
4ms
TG6050, an oncolytic vaccinia virus encoding interleukin-12 and anti-CTLA-4 antibody, favors tumor regression via profound immune remodeling of the tumor microenvironment. (PubMed, J Immunother Cancer)
TG6050 effectively delivers functional IL-12 and @CTLA-4 into the tumor, resulting in strong antitumor activity. The shift towards an inflamed TME correlated with a boost in systemic antitumor T cells. The solid preclinical data and favorable benefit/risk ratio paved the way for the clinical evaluation of TG6050 in metastatic non-small cell lung cancer (NCT05788926 trial in progress).
Journal • Oncolytic virus • IO biomarker
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
|
TG6050
4ms
New P1 trial
|
EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • BRCA (Breast cancer early onset)
|
YSCH-01
5ms
Trial completion
|
HyBryte (synthetic hypericin) • Valchlor (mechlorethamine gel)
5ms
Biomarker screen for efficacy of oncolytic virotherapy in patient-derived pancreatic cancer cultures. (PubMed, EBioMedicine)
Considering the heterogeneity of PDAC and the complexity of biological therapies such as OVs, no single biomarker can explain the spectrum of response patterns. For selection of a particular OV, PDAC molecular subtype, ISG expression as well as activation of distinct signaling and metabolic pathways should be considered. Combination therapies can overcome resistance in specific constellations. Overall, oncolytic virotherapy is a viable treatment option for PDAC, which warrants further development. This study highlights the need for personalised treatment in OVT. By providing all primary data, this study provides a rich source and guidance for ongoing developments.
Journal • Oncolytic virus • IO biomarker
|
LGALS1 (Galectin 1) • CGAS (Cyclic GMP-AMP Synthase)
|
Imlygic (talimogene laherparepvec) • MV-NIS • ParvOryx (parvovirus H-1)
5ms
New P3 trial
|
HyBryte (synthetic hypericin)
5ms
Intravesical instillation-based mTOR-STAT3 dual targeting for bladder cancer treatment. (PubMed, J Exp Clin Cancer Res)
The bi-specific siRNA strategy, encapsulated in an adenovirus, could be a promising tool to augment cancer treatment efficacy and overcome conventional therapy limitations associated with "undruggability." Hence, we propose that dual targeting of mTOR and STAT3 is an advantageous strategy for intravesical therapy using adenoviruses.
Journal
|
CD8 (cluster of differentiation 8) • STAT3 (Signal Transducer And Activator Of Transcription 3)
|
Adstiladrin (nadofaragene firadenovec-vncg) • cretostimogene grenadenorepvec (CG0070)
5ms
MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer (clinicaltrials.gov)
P1/2, N=34, Active, not recruiting, Mayo Clinic | Recruiting --> Active, not recruiting | N=57 --> 34
Enrollment closed • Enrollment change
|
CD4 (CD4 Molecule)
|
MV-NIS
6ms
New trial
|
cretostimogene grenadenorepvec (CG0070)
6ms
"neoBREASTIM": Atezolizumab Plus RP1 Oncolytic Immunotherapy in the NeoAdjuvant Setting of Triple-Negative Breast Cancer (clinicaltrials.gov)
P1/2, N=51, Recruiting, Institut Curie | Not yet recruiting --> Recruiting | Initiation date: Dec 2023 --> Apr 2024
Enrollment open • Trial initiation date • Oncolytic virus
|
HER-2 (Human epidermal growth factor receptor 2)
|
Tecentriq (atezolizumab) • vusolimogene oderparepvec (RP1)
7ms
Preliminary efficacy and safety of YSCH-01 in patients with advanced solid tumors: an investigator-initiated trial. (PubMed, J Immunother Cancer)
The study shows that YSCH-01 injections were safe and well tolerated and exhibited preliminary efficacy in patients with advanced solid tumors, supporting further investigation to evaluate its efficacy and safety.
Journal • Metastases
|
IFNG (Interferon, gamma) • IL6 (Interleukin 6)
|
YSCH-01
7ms
Gut microbiome and gene expression changes during a Phase 1 trial of enadenotucirev and radiotherapy (ESTRO 2024)
Purpose/Objective: The CEDAR trial was a multi-centre phase 1 clinical trial (NCT03916510) in locally advanced rectal cancer patients which combined 25x2Gy chemoradiation with concurrent capecitabine and Enadenotucirev (EnAd), a tumourselective intravenous oncolytic adenovirus. S5230 Radiobiology - Microenvironment Interpatient microbial heterogeneity is greater than dynamic microbiome shifts through treatment in this study. Certain microbiome constituents may be associated with more favourable radiation responses. The absence of significant microbial variation during treatment suggests baseline microbiome features could be further explored as a predictive biomarker.
P1 data
|
ATG5 (Autophagy Related 5) • CDK1 (Cyclin-dependent kinase 1) • HPRT1 (Hypoxanthine Phosphoribosyltransferase 1) • DSG2 (Desmoglein 2)
|
nCounter® PanCancer Immune Profiling Panel
|
capecitabine • enadenotucirev (ColoAd1)
7ms
BOND3: Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin (clinicaltrials.gov)
P3, N=190, Recruiting, CG Oncology, Inc. | N=110 --> 190 | Trial completion date: Jul 2025 --> Dec 2029 | Trial primary completion date: Jan 2024 --> Dec 2027
Enrollment change • Trial completion date • Trial primary completion date
|
cretostimogene grenadenorepvec (CG0070)
7ms
A Transformable Specific-Responsive Peptide for One-Step Synergistic Therapy of Bladder Cancer. (PubMed, Small)
The TSRP is composed of: i) Recognition unit could specifically target and inhibit the biological function of FGFR-1; ii) Transformable unit could self-assembly and trigger nanofibers formation; iii) Reactive unit could specifically cleaved by MMP-2/9 in tumor micro-environment; iv) Immune unit, stimulate the release of immune cells when LTX-315 (Immune-associated oncolytic peptide) exposed...All above processes together contribute to the increasing survival rate of tumor-bearing mice by nearly 4-folds. This work presented a unique design for the biological application of one-step synergistic therapy of bladder cancer.
Journal
|
FGFR1 (Fibroblast growth factor receptor 1) • CD8 (cluster of differentiation 8) • MMP2 (Matrix metallopeptidase 2) • CALR (Calreticulin) • MMP9 (Matrix metallopeptidase 9)
|
Oncopore (ruxotemitide)
7ms
Topical SGX302 for Mild-to-Moderate Psoriasis (clinicaltrials.gov)
P2, N=42, Recruiting, Soligenix | Trial completion date: Dec 2023 --> Jun 2025 | Trial primary completion date: Oct 2023 --> Apr 2025
Trial completion date • Trial primary completion date
7ms
RTB: Evaluate Safety and the Oncolitic Adenovirus VCN-01 Activity in Patients With Refractory Retinoblastoma (clinicaltrials.gov)
P=N/A, N=13, Active, not recruiting, Fundació Sant Joan de Déu | Recruiting --> Active, not recruiting | Phase classification: P1 --> PN/A | Trial completion date: Jun 2022 --> Jul 2024 | Trial primary completion date: Jun 2022 --> Jun 2024
Enrollment closed • Phase classification • Trial completion date • Trial primary completion date • Oncolytic virus
|
RB1 (RB Transcriptional Corepressor 1)
|
RB1 mutation
|
VCN-01
7ms
Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT (clinicaltrials.gov)
P1, N=18, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting
Enrollment closed • Combination therapy
|
PD-L1 (Programmed death ligand 1)
|
Keytruda (pembrolizumab) • Clostridium novyi-NT
8ms
Gut microbiota composition is associated with the efficacy of Delta-24-RGDOX in malignant gliomas. (PubMed, Mol Ther Oncol)
To test this hypothesis, we evaluated the changes in gut microbiota in two mouse cohorts: (1) GSC-005 glioblastoma-bearing mice treated orally with indoximod, an immunotherapeutic agent, or with Delta-24-RGDOX by intratumoral injection and (2) a mouse cohort harboring GL261-5 tumors used to mechanistically evaluate the importance of CD4+ T cells in relation to viroimmunotherapy efficacy. The CD4+ T cell depletion was associated with gut dysbiosis, lower mouse survival, and lower antitumor efficacy of the therapy. These findings suggest that microbiota modulation along the gut-glioma axis contributes to the clinical efficacy and patient survival of viroimmunotherapy treated animals.
Journal • IO biomarker
|
CD4 (CD4 Molecule) • TNFSF4 (TNF Superfamily Member 4)
|
indoximod (NLG8189) • DNX-2440
8ms
DNX-2440 for Resectable Colorectal Liver Metastasis (clinicaltrials.gov)
P1, N=30, Suspended, DNAtrix, Inc. | Trial completion date: Dec 2023 --> Dec 2026 | Recruiting --> Suspended | Trial primary completion date: Jul 2022 --> Jul 2026
Trial completion date • Trial suspension • Trial primary completion date • Oncolytic virus
|
DNX-2440
8ms
Enrollment closed • Enrollment change • Metastases
|
imifoplatin (PT-112)